## BI BUFFER SOLUTIONS

100 Majestic Way, Bangor, PA 18013 / www.biospectra.us

Effective Date:	11-Ju1-2024	11-Ju1-2027	: Date of Next Review
Prepared By:	Carissa Albert	BSI-COA-0131 v.6.2	: Supersedes
QA/QC Approval:	Jaron Hughes	Wayne Talamonti	: Management Approval
Reason for Revision:	See Revision History in MasterControl		

## CERTIFICATE OF ANALYSIS

## L-CYSTINE diHCl

## BIO PHARMA GRADE / LCYS-4250-25

LOT: LCYS-L02-1024-0024

 $C_6H_{12}N_2O_4S_2 \cdot 2HC1 + F.W. 313.22 g/mol. + CAS# 30925-07-6$ 

Retest Date: 05/31/26

Manufacturing/Packaging Date: 10/02/24 Packaging Site: 100 Majestic Way, Bangor PA, 18013

Analysis	SPECIFICATION	TEST RESULT		
Appearance and Color	White to Slightly Yellow Crystalline Powder	White to Slightly Yellow Crystalline Powder		
Assay (Dried Basis)	98.0% - 102.0%	99.8%		
Bioburden	$\leq 100 \text{ CFU/g}$	< 10 CFU/g		
Chloride	22.2% - 23.5%	22.6%		
Endotoxin	<0.02 EU/mg	< 0.02 EU/mg		
Heavy Metals (Pb)	<10 ppm	< 0.15 ppm		
Identification (IR Spectrum)	Passes Test	Passes Test		
Loss on Drying @ 105°C	≤ 0.5%	< 0.5%		
pH (0.1% soln.)	Report	2.38 @ 23.5°C		
Residue on Ignition	≤ 0.1%	< 0.1%		
Specific Rotation (Free Basis) @ 20°C	-225.0° to -215.0°	-222.0°		
Solubility	Passes Test	Passes Test		

**COUNTRY OF ORIGIN:** India

INTENDED USE: Material represented by this Certificate of Analysis is suitable for use as a process chemical. It is GMP manufactured by the approved supplier in accordance with the approved supplier's ISO 9001:2015 certified management system. The material represented by this Certificate of Analysis is not suitable to be used as an Active Pharmaceutical Ingredient, Drug, Drug Product or Household Item.

RETEST DATE: The retest date is obtained from the approved supplier's certificate of analysis.

Prepared by:	A	nu	Melall	Date:	10/4/24	Job Title:	QATECNI
		,	,				

DCN: BSI-COA-0131 v.6.3

Reviewed by: Javor Burgh Date: 10/4/74 Job Title: Of Supervisor